Skip to main content

Can Ozempic cause personality changes​ or depression?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on Aug 29, 2025.

Official Answer by Drugs.com

Ozempic (semaglutide) is a GLP-1 receptor agonist primarily prescribed for type 2 diabetes and, off-label, for weight loss. Recently, there have been reports and discussions about whether Ozempic can cause personality changes or depression. While there have been case reports and anecdotal evidence on social media, the majority of scientific reviews have not found an association between Ozempic and suicidal thoughts or actions.

Can Ozempic Cause Depression?

The question, "Can Ozempic cause depression?" is gaining attention as users and healthcare providers report mood-related side effects. Scientific evidence suggests that while some individuals may experience changes in mood or personality, these effects are not universal.

Most reports are observational, and there is currently no definitive proof that Ozempic directly causes depression. However, the drug’s influence on brain pathways involved in reward and mood regulation raises concerns, especially for people with pre-existing mental health conditions. Patients should consult their healthcare providers to monitor any emotional or behavioral changes during treatment, ensuring prompt management if needed.

Evidence on Personality Changes and Depression From Ozempic

Mood changes, such as depression, are not mentioned as common side effects in the manufacturer labeling for Ozempic. Interestingly, there is a warning about suicidal behavior and ideation in the Wegovy package insert (another brand name for semaglutide approved for weight loss), but it is based on reports of this side effect with other weight management products.

Regulatory agencies like the FDA and EMA have closely examined safety data related to Ozempic, including thousands of adverse event reports submitted through systems like the FDA’s Adverse Event Reporting System (FAERS). While reports of depression, mood changes, and even suicidal ideation have been documented, these do not confirm a direct cause-and-effect relationship. Ongoing investigations by the FDA and the European Medicines Agency continue to assess whether there is a true causal relationship.

Below is a summary of research on mood changes from Ozempic:

Related questions

How Ozempic Affects Your Brain

Understanding why Ozempic might cause mood changes requires looking at how this diabetes medication actually reaches and affects your brain. Unlike smaller drugs that can easily cross the protective barrier around your brain, semaglutide (the active ingredient in Ozempic) is a large molecule that doesn't appear to get through normal brain barriers.

Instead, Ozempic accesses your brain through special "gateway" regions that don't have complete protective barriers. These areas, including parts of your brainstem and hypothalamus, allow larger molecules to enter. Once there, specialized cells called tanycytes act like shuttles, transporting the medication deeper into brain regions that control mood, appetite, and behavior.

Once in your brain, Ozempic activates receptors that are normally triggered by a hormone called GLP-1, which your body naturally produces in your intestines and brain. These same brain regions that Ozempic targets are also involved in regulating your mood, motivation, and emotional responses. When Ozempic changes how these areas function, it can inadvertently affect how you feel emotionally, not just how hungry you are.

Why Some People Experience Ozempic Personality Changes and Mood Swings

Many people report feeling "different" on Ozempic, such as being less interested in activities they used to enjoy, changes in their social behavior, or shifts in their emotional responses. These personality changes may be linked to how Ozempic affects your brain's reward system, the network of brain regions that controls motivation and pleasure. Your brain's reward system relies heavily on a chemical called dopamine, which makes you feel good when you do something enjoyable. Examples include eating your favorite food, spending time with friends, or pursuing a hobby.

Ozempic appears to change how this dopamine system functions, potentially making it less responsive to things that used to bring you pleasure. However, more studies are needed to confirm the relationship and mechanisms behind Ozempic and personality changes.

When to Get Medical Help

Monitor mood and behavior closely when starting Ozempic, and report any new or worsening depression, anxiety, or unusual mood changes to a healthcare professional immediately. Warning signs that warrant immediate medical attention include:

Do not discontinue Ozempic without medical advice, as untreated diabetes or obesity can also impact mental health.

Summary

While some patients taking Ozempic report mood changes, anxiety, or depressive symptoms that they interpret as personality changes, these effects are not widely documented in clinical trials or official prescribing information. Large-scale studies have not confirmed a direct causal link. Patients experiencing mood changes should promptly discuss these symptoms with their healthcare provider to ensure appropriate management.

References
  1. Arillotta, D., et. al. 2023. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain sciences, 13(11), 1503. https://doi.org/10.3390/brainsci13111503
  2. Daniels, D., & Mietlicki-Baase, E. G. (2019). Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?. Diabetes, 68(1), 15–17. https://doi.org/10.2337/dbi18-0045
  3. De Giorgi, R., et. al. 2024. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. In: The Lancet. DOI: https://doi.org/10.1016/j.eclinm.2024.102726
  4. Dong, M., Wen, S., & Zhou, L. (2022). The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. Diabetes, metabolic syndrome and obesity : targets and therapy, 15, 2583–2597. https://doi.org/10.2147/DMSO.S375559
  5. European Medicines Agency. 2024. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. Accessed on May 7, 2025 at https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024
  6. Kornelius, E., Huang, J. Y., Lo, S. C., Huang, C. N., & Yang, Y. S. (2024). The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific reports, 14(1), 24433. https://doi.org/10.1038/s41598-024-75965-2
  7. Li, J. R., et. al. 2023. Case Report: Semaglutide-associated depression: a report of two cases. Frontiers in psychiatry, 14, 1238353. https://doi.org/10.3389/fpsyt.2023.1238353
  8. Manoharan, S. V. R. R., et. al. 2024. GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide). Innovations in clinical neuroscience, 21(4-6), 25–26. PMCID: PMC11208009  PMID: 38938530
  9. Ozempic [package insert]. Updated 2025. Novo Nordisk. Accessed on May 6, 2025 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  10. Schoretsanitis, G., et al. 2024. Disproportionality analysis from World Health Organization Data on semaglutide, liraglutide, and suicidality. JAMA Network Open. DOI: https://doi.org/10.1001/jamanetworkopen.2024.23385
  11. US Food and Drug Administration. 2024. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Accessed on May 7, 2025 at https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type
  12. Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024). Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA internal medicine, 184(11), 1290–1300. https://doi.org/10.1001/jamainternmed.2024.4346
  13. Wang, W., et. al. 2024. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024 Jan;30(1):168-176. DOI: https://doi.org/10.1038/s41591-023-02672-2

Read next

Ozempic Mounjaro Wegovy & Zepbound: Weight Loss Compared

Ozempic, Mounjaro, Wegovy and Zepbound can all lead to long-term weight loss, but only Wegovy and Zepbound are approved by the FDA for this use. In studies, Zepbound has led to a 21% weight loss in adults using the highest dose, while Wegovy has led to about a 15% weight loss.

Continue reading

Wegovy vs Ozempic: Which is Right for You?

Both Wegovy and Ozempic contain semaglutide, but Wegovy is prescribed for long-term weight management while Ozempic is used to control blood sugar levels in type 2 diabetes and help protect kidney function. They both lower the risk for heart-related complications, but they differ in other approved uses, doses, target populations and costs.

Continue reading

How long does it take for Ozempic to work?

Your blood glucose (sugar) levels should start to fully decline within the first week after you start using Ozempic (semaglutide) at your regular dose. However, the full effect can take 8 weeks or longer, as this is a long-acting medication that is injected only once per week. Continue reading

See also:

Related medical questions

Drug information

Related support groups